SecBot SecBot
PRESS-RELEASE ·Filed Aug 13, 2026

ZNTL

ZENTALIS PHARMACEUTICALS
BEARISH
Impact 6/10
Horizonimmediate Processed3mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

The dilutive offering at $3.50 per share, below the current market price, will pressure ZNTL shares near term. Monitor the August 17 close and any subsequent insider selling. The company's cash runway extends but at the cost of significant shareholder dilution; watch for updates on azenosertib clinical data as the primary catalyst for recovery.

DirectionBearish
Confidencehigh
Horizonimmediate

azenosertib

◆ Mixed Named in this press release
Impact
Phase
Phase 2 (registration-intent) with Phase 3 confirmatory trial initiated
Time to market
If the DENALI Part 2 readout in 1H 2027 is positive, Zentalis plans to discuss an accelerated approval pathway with the FDA in 2027. Under an accelerated approval scenario, a potential FDA decision could come in 2028 at the earliest, though the timeline is uncertain and depends on regulatory feedback.
Next catalyst
None dated

What to watchThe next major catalyst is the DENALI Part 2 topline readout expected in 1H 2027 (roughly 2-7 months away). A positive readout could support an accelerated approval filing with the FDA; a negative or mixed readout would likely devastate the stock given Zentalis is a single-asset company. The August 2026 delay from year-end 2026 to 1H 2027 was a negative signal, and the stock now trades at $1.74, well below the $3.50 August offering price. Monitor FDA discussions in 2027 and any pre-readout data disclosures.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.56
T+0 close · Aug 13, 2026 · via day close
Latest settled
−51.12%
T+60 · $1.74
Vs SPY
−48.08%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $3.56entry
  2. T+1 · 3mo ago +4.07%α +4.55% · $3.71
  3. T+5 · 3mo ago +7.44%α +8.81% · $3.83
  4. T+20 · 2mo ago −1.69%α +0.31% · $3.50
  5. T+60 · 8d ago −51.12%α −48.08% · $1.74

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zentalis Pharmaceuticals priced an underwritten public offering of 23 million shares at $3.50 per share, expecting ~$80.5 million in gross proceeds. The dilutive offering, representing ~20% of shares outstanding based on market cap, is intended to fund clinical trials and pre-commercial activities for its lead WEE1 inhibitor azenosertib. The stock trades at $307M market cap, and the offering price of $3.50 is at a discount to the prior close, signaling near-term dilution pressure.

Key Financial Metrics

Deal Value
$80.5M

Key Facts

  • 23,000,000 shares priced at $3.50 per share in an underwritten public offering
  • Expected gross proceeds of approximately $80.5 million
  • Underwriters granted a 30-day option to purchase up to an additional 3,450,000 shares
  • Offering expected to close on August 17, 2026
  • Proceeds to fund clinical trials, preclinical studies, regulatory filings, manufacturing, and pre-commercial activities
  • TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are joint bookrunners

Financial Impact

~$80.5M gross proceeds from 23M shares at $3.50; dilution of ~20% of current shares outstanding based on $307M market cap

dilutioncashshare count

Risk Factors

  • Dilution of ~20% from the offering, reducing EPS and ownership
  • Offering priced at $3.50 may signal weak demand or urgency for capital
  • Underwriters' option for additional 3.45M shares could add further dilution
  • Clinical-stage biotech with no approved product; azenosertib regulatory and commercial risk remains high

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
63% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3345070

Track record

18 reports on ZNTL

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +51.42% at T+60 after the Aug 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.62 Now $1.60 −1.23% settles Feb 12
  2. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.80 Now $1.60 +11.11% settles Feb 8
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $2.06 Now $1.60 −22.33% settles Jan 26
  4. Oct 18, 202629d ago Press Release Bullish 7/10 Entry $2.30 Now $1.60 −30.43% settles Jan 14
  5. Oct 1, 20266w ago Press Release Neutral 2/10 Entry $2.52 Now $1.60 −36.51% settles Dec 29
  6. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $3.71 to $1.80 Now $1.60 +56.82% ▲ +51.42% +48.47% vs SPY
  7. Aug 13, 202613w ago Press Release Bearish 6/10 Viewing Entry $3.56 to $1.74 Now $1.60 +55.06% ▲ +51.12% +48.08% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.75 to $4.03 Now $1.60 −57.33% ▲ +7.47% +4.20% vs SPY
  9. Jun 1, 202624w ago Press Release Neutral 2/10 Entry $3.95 to $3.89 Now $1.60 −59.49% ▼ −1.52% −2.64% vs SPY
  10. May 21, 202625w ago Press Release Bullish 6/10 Entry $4.06 to $3.68 Now $1.60 −60.59% ▼ −9.36% −12.55% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 9h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026